Hennion & Walsh Asset Management, Inc. Lexicon Pharmaceuticals, Inc. Transaction History
Hennion & Walsh Asset Management, Inc.
- $2.35 Billion
- Q2 2025
A detailed history of Hennion & Walsh Asset Management, Inc. transactions in Lexicon Pharmaceuticals, Inc. stock. As of the latest transaction made, Hennion & Walsh Asset Management, Inc. holds 793,400 shares of LXRX stock, worth $912,409. This represents 0.03% of its overall portfolio holdings.
Number of Shares
793,400
Previous 830,054
4.42%
Holding current value
$912,409
Previous $473,000
59.2%
% of portfolio
0.03%
Previous 0.02%
Shares
5 transactions
Others Institutions Holding LXRX
# of Institutions
135Shares Held
199MCall Options Held
310KPut Options Held
77.3K-
Artal Group S.A. Luxembourg, N4136MShares$157 Million100.0% of portfolio
-
Black Rock Inc. New York, NY9.89MShares$11.4 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.56MShares$11 Million0.0% of portfolio
-
Schonfeld Strategic Advisors LLC New York, NY8.21MShares$9.44 Million0.03% of portfolio
-
Geode Capital Management, LLC Boston, MA3.69MShares$4.24 Million0.0% of portfolio
About LEXICON PHARMACEUTICALS, INC.
- Ticker LXRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 188,726,000
- Market Cap $217M
- Description
- Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; ...